Pharmacologia2044-46482044-4656Science International10.3923/pharmacologia.2012.61.74WilliamsD.P. LawrenceAmy MengXiaoli 3201233Background: Patients with alkaptonuria are exposed to a high body-burden of homogentisic acid, due to a genetic deficiency of the enzyme homogentisate 1,2-dioxygenase. Younger patients appear to be more robust at withstanding or adapting to this chemical stress. As the patients age, the deposition of ochronotic pigments appears in connective tissues. This is thought to lead to the weakening of tissues and development of osteoarthritis. Currently, there is no marketed drug to treat alkaptonuria and the disease is managed through non-steroidal anti-inflammatory agents. Results: This review considers potential pharmacological strategies for increasing the excretion of homogentisic acid, with the goal of reducing the exposure of patient tissues to this acid. In order to define these strategies, we need to understand the processes by which low molecular weight compounds are handled by the body and enzymatically manipulated into forms which are more easily excreted. These processes are more commonly referred to as drug metabolism and are well understood within the pharmaceutical industry, who are required to design drugs that can reach pharmacological targets at a concentration required to achieve efficacy. Drug metabolism consists of phase I and phase II reactions. Phase I reactions (oxidation, reduction or hydrolysis) are required to increase the chemical reactivity of a molecule by adding or uncovering a more reactive chemical group. Phase II reactions add a polar, hydrophilic conjugate molecule (glucuronide, sulphate, GSH), increasing the renal excretion. In certain cases, drug metabolism can produce reactive and potentially toxic metabolites which can bind to DNA leading to carcinogenesis, or bind to protein leading to either direct organ toxicity (e.g., paracetamol) or immune-mediated toxicity (e.g., halothane). Conclusion: A better understanding of these processes within a disease such as alkaptonuria will help design rational patient management strategies through increasing the excretion and reducing the overall body burden of homogentisic acid.]]>Alam, J., D. Stewart, C. Touchard, S. Boinapally, A.M. Choi and J.L. Cook,19992742607126078Andringa, K.K., M.L. Bajt, H. Jaeschke and S.M. Bailey,2008177188197Biasi, D., A. Carletto, P. Caramaschi, P. Bellavite and G. Andrioli et al.,199513623627Buetler, T.M., E.P. Gallagher, C. Wang, D.L. Stahl, J.D. Hayes and D.L. Eaton,19951354557Burchell, B., D.W. Nebert, D.R. Nelson, K.W. Bock and T. Iyanagi et al.,199110487494Campian, E.C., J. Cai and F.W. Benz,2002140279291Coles, B., I. Wilson, P. Wardman, J.A. Hinson, S.D. Nelson and B. Ketterer,1988264253260Copple, I.M., C.E. Goldring, R.E. Jenkins, A.J. Chia and L.E. Randle et al.,20084812921301Copple, I.M., C.E. Goldring, N.R. Kitteringham and B.K. Park,2010246233266Corley, R.A., J.C. English, T.S. Hill, L.A. Fiorica and D.A. Morgott,2000165163174Coulter, E.M., J. Farrell, K.L. Mathews, J.L. Maggs and C.K. Pease et al.,2007320885892Coulter, E.M., C. Jenkinson, J. Farrell, S.N. Lavergne and C. Pease et al.,2010+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals.]]>130161174Coulter, E.M., C. Jenkinson, Y. Wu, J. Farrell and B. Foster et al.,2008128897905Davis, D.C., W.Z. Potter, D.J. Jollow and J.R. Mitchell,19741420992109Devling, T.W., C.D. Lindsay, L.I. McLellan, M. McMahon and J.D. Hayes,200510272807285Di Pietro, G., L.A. Magno and F. Rios-Santos,20106153170Druckova, A., R.L. Mernaugh, A.J. Ham and L.J. Marnett,2007in vivo in the rat.]]>2013931408Fiser-Herman, M. and M. Petrovacki,19583248252Gelboin, H.V., S.S. Park, T. Aoyama, T. Fujino, C.L. Crespi and F.J. Gonzalez,199021316Gillette, J.R.,19742327852794Gillette, J.R.,19742329272938Goldring, C.E., N.R. Kitteringham, R. Elsby, L.E. Randle and Y.N. Clement et al.,2004in vivo by acetaminophen in CD-1 mice.]]>3912671276Gonzalez, F.J.,1991111202213Gonzalez, F.J., T. Aoyama and H.V. Gelboin,1990340B7786Hanzlik, R.P., Y.M. Koen, B. Theertham, Y. Dong and J. Fang,200789595Harris, S.L. and A.J. Levine,20052428992908Hayes, J.D. and M. McMahon,2001174103113Helliwell, T.R., J.A. Gallagher and L. Ranganath,200853503512Henderson, C.J., C.R. Wolf, N. Kitteringham, H. Powell, D. Otto and B.K. Park,2000971274112745Ho, K.J., P.Q. Chen, C.Y. Chang and F.J. Lu,200059338341Ikehata, K., T.G. Duzhak, N.A. Galeva, T. Ji, Y.M. Koen and R.P. Hanzlik,2008in vivo.]]>2114321442Itoh, K., N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel and M. Yamamoto,1999137686Itoh, K., N. Wakabayashi, Y. Katoh, T. Ishii, T. O`Connor and M. Yamamoto,20038379391Jordan, R.A. and T.F. Woolf,1987278790Kalgutkar, A.S. and J.R. Soglia,2005191142Koen, Y.M., N.V. Gogichaeva, M.A. Alterman and R.P. Hanzlik,2007in vivo.]]>20511519Kola, I. and J. Landis,20043711716La Du, B.N., W.M. O`Brien and V.G. Zannoni,196258187Larsson, A., B. Mattsson, L. Hagenfeldt and P. Moldeus,19831355764Lee, J.M. and J.A. Johnson,200437139143Liebler, D.C.,200821117128Martin, J.P., Jr. and B. Batkoff,19873241250Matthews, A.M., J.A. Hinson, D.W. Roberts and N.R. Pumford,1997907782McMahon, M., K. Itoh, M. Yamamoto and J.D. Hayes,20032782159221600Monks, T.J., R.P. Hanzlik, G.M. Cohen, D. Ross and D.G. Graham,1992112216Myers, T.G., E.C. Dietz, N.L. Anderson, E.A. Khairallah, S.D. Cohen and S.D. Nelson,19958403413Okawa, H., H. Motohashi, A. Kobayashi, H. Aburatani, T.W. Kensler and M. Yamamoto,20063397988Park, B.K., N.R. Kitteringham, J.L. Maggs, M. Pirmohamed and D.P. Williams,200545177202Park, B.K., M. Pirmohamed and N.R. Kitteringham,199811969988Patel, D.K., A. Hesse, A. Ogunbona, L.J. Notarianni and P.N. Bennett,19909131136Phornphutkul, C., W.J. Introne, M.B. Perry, I. Bernardini and M.D. Murphey et al.,200234721112121Pirmohamed, M., N.R. Kitteringham and B.K. Park,199411114144Poet, T.S., H. Wu, J.C. English and R.A. Corley,200482925Prestera, T., Y. Zhang, S.R. Spencer, C.A. Wilczak and P. Talalay,199333281296Proudfoot, A.T., E.P. Krenzelok and J.A. Vale,200442126Qiu, Y., L.Z. Benet and A.L. Burlingame,1998in vivo in mice using two dimensional gel electrophoresis and mass spectrometry.]]>2731794017953Randle, L.E., C.E. Goldring, C.A. Benson, P.N. Metcalfe, N.R. Kitteringham, B.K. Park and D.P. Williams,2008243249260Roberts, S.A., V.F. Price and D.J. Jollow,1990In vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide.]]>105195208Shin, N.Y., Q. Liu, S.L. Stamer and D.C. Liebler,200720859867Shipkova, M., H. Beck, A. Voland, V.W. Armstrong, H.J. Grone, M. Oellerich and E. Wieland,2004427282738Skarzynski, B., M. Sarnecka-Keller and J. Frendo,19627243247Stoner, R. and B.B. Blivaiss,1967105360Suwannarat, P., K. O`Brien, M.B. Perry, N. Sebring and I. Bernardini et al.,200554719728Tephly, T.R. and B. Burchell,199011276279Venugopal, R. and A.K. Jaiswal,1996931496014965Venugopal, R. and A.K. Jaiswal,19981731453156Wakabayashi, N., K. Itoh, J. Wakabayashi, H. Motohashi and S. Noda et al.,2003Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation.]]>35238245Wild, A.C., H.R. Moinova and R.T. Mulcahy,19992743362733636Williams, D.P., N.R. Kitteringham, D.J. Naisbitt, M. Pirmohamed, D.A. Smith and B.K. Park,20023351366Williams, D.P. and B.K. Park,2003810441050Williams, R.T.,1971179141154Wolff, J.A., B. Barshop, W.L. Nyhan, J. Leslie and J.E. Seegmiller et al.,198926140144Wong, H.L. and D.C. Liebler,200821796804Woolf, T.F. and R.A. Jordan,1987271517Yan, Z. and G.W. Caldwell,200328223232Zannoni, V.G., N. Lomtevas and S. Goldfinger,196917794105